Recommended Topic Related To:

Kionex

"The U.S. Food and Drug Administration today approved Procysbi (cysteamine bitartrate) for the management of nephropathic cystinosis in children and adults. Procysbi was granted orphan product designation because it is intended to treat a rare dis"...

Kionex

Indications
Dosage
How Supplied

INDICATIONS

Kionex® (sodium polystyrene sulfonate) is indicated for the treatment of hyperkalemia.

DOSAGE AND ADMINISTRATION

Suspension of this drug should be freshly prepared and not stored beyond 24 hours.

The average daily adult dose of the resin is 15 g to 60 g. This is best provided by administering 15 grams (approximately 4 level teaspoons) of Kionex® (sodium polystyrene sulfonate) one to four times daily. One gram of Kionex® (sodium polystyrene sulfonate) contains 4.1 mEq of sodium; one level teaspoon contains approximately 3.5 grams of Kionex® (sodium polystyrene sulfonate) and 15 mEq of sodium. (A heaping teaspoon may contain as much as 10 to 12 grams of Kionex® (sodium polystyrene sulfonate) .) Since the in vivo efficiency of sodium-potassium exchange resins is approximately 33 percent, about one third of the resin's actual sodium content is being delivered to the body.

In smaller children and infants, lower doses should be employed by using as a guide a rate of 1 mEq of potassium per gram of resin as the basis for calculation.

Each dose should be given as a suspension in a small quantity of water or, for greater palatability, in syrup. The amount of fluid usually ranges from 20 to 100mL, depending on the dose, or may be simply determined by allowing 3 to 4 mL per gram resin.

The resin may be introduced into the stomach through a plastic tube and, if desired, mixed with a diet appropriate for a patient in renal failure.

The resin may also be given, although with less effective results, in an enema consisting (for adults) of 30 g to 50 g every six hours. Each dose is administered as a warm emulsion (at body temperature) in 100 mL of aqueous vehicle, such as sorbitol. The emulsion should be agitated gently during administration. The enema should be retained as long as possible and followed by a cleansing enema.

After an initial cleansing enema, a soft, large size (French 28) rubber tube is inserted into the rectum for a distance of about 20 cm, with the tip well into the sigmoid colon, and taped in place. The resin is then suspended in the appropriate amount of aqueous vehicle at body temperature and introduced by gravity, while the particles are kept in suspension by stirring. The suspension is flushed with 50 mL or 100 mL of fluid, following which the tube is clamped and left in place. If back leakage occurs, the hips are elevated on pillows or a knee-chest position is taken temporarily. A somewhat thicker suspension may be used, but care should be taken that no paste is formed, because the latter has a greatly reduced exchange surface and will be particularly ineffective if deposited in the rectal ampulla. The suspension is kept in the sigmoid colon for several hours, if possible. Then the colon is irrigated with nonsodium containing solution at body temperature in order to remove the resin. Two quarts of flushing solution may be necessary. The returns are drained constantly through a Y tube connection. Particular attention should be paid to this cleansing enema when sorbitol has been used.

The intensity and duration of therapy depend upon the severity and resistance of hyperkalemia.

Kionex® (sodium polystyrene sulfonate) should not be heated for to do so may alter the exchange properties of the resin.

HOW SUPPLIED

Kionex® (sodium polystyrene sulfonate) is available as a cream to light brown, finely ground powder in jars of 1 pound.

Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP ControlledRoom Temperature].

Dispense in a tight, light-resistant container as defined in the USP.

Kionex® (Sodium Polystyrene Sulfonate, USP) is available as a powder in containers of: 454 grams (One Pound)

NDC 0574-2004-16

Packaged by: Paddock Laboratories, Inc.Minneapolis, MN 55427. FDA rev date: 9/17/2007

Last reviewed on RxList: 10/8/2007
This monograph has been modified to include the generic and brand name in many instances.

Indications
Dosage
How Supplied
A A A

Kionex - User Reviews

Kionex User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Kionex sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.


NIH talks about Ebola on WebMD